Bausch + Lomb Corp. says its 2023 results “set the tone” for its "largest" year for product launches in 2024 but the sound investors likely want to hear most is the completion of its separation from majority owner Bausch Health Companies Inc.
The Canadian firm’s eye health dietary supplements Ocuvite and PreserVision continued as its top sellers in 2023 and in the fourth quarter, with its ReNu and Biotrue contact lens solutions and its Lumify (brimonidine tartrate 0
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?